Ionis Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.
CEOBrett P. Monia
CEOBrett P. Monia
Employees1,069
Employees1,069
HeadquartersCarlsbad, California
HeadquartersCarlsbad, California
Founded1989
Founded1989
Employees1,069
Employees1,069
IONS Key Statistics
Market cap13.41B
Market cap13.41B
Price-Earnings ratio-48.34
Price-Earnings ratio-48.34
Dividend yield—
Dividend yield—
Average volume2.74M
Average volume2.74M
High today$83.00
High today$83.00
Low today$81.50
Low today$81.50
Open price$82.62
Open price$82.62
Volume850.57K
Volume850.57K
52 Week high$83.00
52 Week high$83.00
52 Week low$23.95
52 Week low$23.95
Stock Snapshot
As of today, Ionis Pharmaceuticals(IONS) shares are valued at $82.73. The company's market cap stands at 13.41B, with a P/E ratio of -48.34.
On 2025-11-29, Ionis Pharmaceuticals(IONS) stock moved within a range of $81.50 to $83.00. With shares now at $82.73, the stock is trading +1.5% above its intraday low and -0.3% below the session's peak.
Trading activity shows a volume of 850.57K, compared to an average daily volume of 2.74M.
The stock's 52-week range extends from a low of $23.95 to a high of $83.00.
The stock's 52-week range extends from a low of $23.95 to a high of $83.00.
IONS News
Simply Wall St 8h
Why Ionis Pharmaceuticals Is Up 8.7% After Donidalorsen EMA Milestone and $700 Million Offering NewsIonis Pharmaceuticals recently received a positive opinion from the European Medicines Agency’s Committee for Donidalorsen, a drug for hereditary angioedema, wi...
Analyst ratings
71%
of 24 ratingsBuy
70.8%
Hold
29.2%
Sell
0%
People also own
Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.